The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

Michael M. Boyiadzis, Ivan Aksentijevich, Daniel A. Arber, John Barrett, Renier J. Brentjens, Jill Brufsky, Jorge Cortes, Marcos De Lima, Stephen J. Forman, Ephraim J. Fuchs, Linda J. Fukas, Steven D. Gore, Mark R. Litzow, Jeffrey S. Miller, John M. Pagel, Edmund K. Waller, Martin S. Tallman

Research output: Contribution to journalArticlepeer-review

Abstract

Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.

Original languageEnglish (US)
Article numbere000810
JournalJournal for ImmunoTherapy of Cancer
Volume8
Issue number2
DOIs
StatePublished - Oct 19 2020

Keywords

  • antineoplastic protocols
  • chimeric antigen
  • guidelines as topic
  • hematological neoplasms
  • immunotherapy
  • receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia'. Together they form a unique fingerprint.

Cite this